These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 23806607

  • 1. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses.
    Farina A, Dumonceau JM, Antinori P, Annessi-Ramseyer I, Frossard JL, Hochstrasser DF, Delhaye M, Lescuyer P.
    Biochim Biophys Acta; 2014 May; 1844(5):1018-25. PubMed ID: 23806607
    [Abstract] [Full Text] [Related]

  • 2. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis.
    Lukic N, Visentin R, Delhaye M, Frossard JL, Lescuyer P, Dumonceau JM, Farina A.
    Biochim Biophys Acta; 2014 May; 1844(5):1026-33. PubMed ID: 23872482
    [Abstract] [Full Text] [Related]

  • 3. The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma.
    Rose JB, Correa-Gallego C, Li Y, Nelson J, Alseidi A, Helton WS, Allen PJ, D'Angelica MI, DeMatteo RP, Fong Y, Kingham TP, Kowdley KV, Jarnagin WR, Rocha FG.
    PLoS One; 2016 May; 11(3):e0150195. PubMed ID: 26974538
    [Abstract] [Full Text] [Related]

  • 4. Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses.
    Severino V, Dumonceau JM, Delhaye M, Moll S, Annessi-Ramseyer I, Robin X, Frossard JL, Farina A.
    Gastroenterology; 2017 Aug; 153(2):495-504.e8. PubMed ID: 28479376
    [Abstract] [Full Text] [Related]

  • 5. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
    Zabron AA, Horneffer-van der Sluis VM, Wadsworth CA, Laird F, Gierula M, Thillainayagam AV, Vlavianos P, Westaby D, Taylor-Robinson SD, Edwards RJ, Khan SA.
    Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
    [Abstract] [Full Text] [Related]

  • 6. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
    Ince AT, Yıldız K, Baysal B, Danalıoğlu A, Kocaman O, Tozlu M, Gangarapu V, Sarbay Kemik A, Uysal Ö, Şentürk H.
    Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
    [Abstract] [Full Text] [Related]

  • 7. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC.
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [Abstract] [Full Text] [Related]

  • 8. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer.
    Farina A, Dumonceau JM, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P.
    J Proteome Res; 2009 Jan; 8(1):159-69. PubMed ID: 19055478
    [Abstract] [Full Text] [Related]

  • 9. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
    Budzynska A, Nowakowska-Dulawa E, Marek T, Boldys H, Nowak A, Hartleb M.
    J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
    [Abstract] [Full Text] [Related]

  • 10. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis.
    Alvaro D, Macarri G, Mancino MG, Marzioni M, Bragazzi M, Onori P, Corradini SG, Invernizzi P, Franchitto A, Attili AF, Gaudio E, Benedetti A.
    Ann Intern Med; 2007 Oct 02; 147(7):451-9. PubMed ID: 17909206
    [Abstract] [Full Text] [Related]

  • 11. Serum total antioxidant capacity to discriminate benign from malignant causes of biliary obstruction.
    Beyazıt Y, Koçak E, Tanoğlu A.
    Turk J Gastroenterol; 2014 Oct 02; 25(5):592-3. PubMed ID: 25417631
    [No Abstract] [Full Text] [Related]

  • 12. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
    Tischendorf JJ, Krüger M, Trautwein C, Duckstein N, Schneider A, Manns MP, Meier PN.
    Endoscopy; 2006 Jul 02; 38(7):665-9. PubMed ID: 16673310
    [Abstract] [Full Text] [Related]

  • 13. Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Malignant and Benign Biliary Obstructions.
    Abdel-Razik A, ElMahdy Y, Hanafy EE, Elhelaly R, Elzehery R, M Tawfik A, Eldars W.
    Am J Med Sci; 2016 Mar 02; 351(3):259-64. PubMed ID: 26992254
    [Abstract] [Full Text] [Related]

  • 14. Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis.
    Beyazit Y, Kekilli M, Ibis M, Kurt M, Sayilir A, Onal IK, Purnak T, Oztas E, Tas A, Yesil Y, Arhan M.
    Hepatogastroenterology; 2012 Mar 02; 59(117):1469-73. PubMed ID: 22683963
    [Abstract] [Full Text] [Related]

  • 15. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
    Chen WM, Wei KL, Chen YS, Chang PJ, Tung SY, Chang TS, Huang HC, Shen CH, Hsieh YY, Wu CS.
    World J Surg Oncol; 2016 May 04; 14():140. PubMed ID: 27142076
    [Abstract] [Full Text] [Related]

  • 16. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma.
    Chen J, Liang J, Xu B, Liang J, Ma M, Wang Z, Zeng G, Xu Q, Liang L, Lai J, Huang L.
    J Gastrointest Cancer; 2024 Jun 04; 55(2):800-808. PubMed ID: 38280173
    [Abstract] [Full Text] [Related]

  • 17. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues.
    Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F.
    J Proteome Res; 2009 Aug 04; 8(8):4092-103. PubMed ID: 19569727
    [Abstract] [Full Text] [Related]

  • 18. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study.
    Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, Cameron R, Hashimoto Y, Shah JN.
    Gastrointest Endosc; 2014 Jul 04; 80(1):97-104. PubMed ID: 24559784
    [Abstract] [Full Text] [Related]

  • 19. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G, Teli M, Jardine N, Puntis MC.
    Hepatobiliary Pancreat Dis Int; 2009 Dec 04; 8(6):620-6. PubMed ID: 20007080
    [Abstract] [Full Text] [Related]

  • 20. Brush cytology in malignant biliary obstruction.
    Singh V, Bhasin S, Nain CK, Gupta SK, Singh G, Bose SM.
    Indian J Pathol Microbiol; 2003 Apr 04; 46(2):197-200. PubMed ID: 15022908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.